| Description | SY-LB-35, a potent bone morphogenetic protein (BMP) receptor agonist, significantly enhances cell number and viability in the C2C12 myoblast cell line. It promotes cell cycle progression, particularly towards the S and G2/M phases. Additionally, SY-LB-35 activates both canonical Smad and non-canonical intracellular signaling pathways, including PI3K/Akt, ERK, p38, and JNK [1]. |
| In vitro | SY-LB-35 (0.01-1000 μM; 24 h) stimulates significant increases in cell number and cell viability of C2C12 myoblast cell line [1]. SY-LB-35 (0.01-10 μM; 30 min or 15 min) stimulates Smad phosphorylation and nuclear translocation, activates the PI3K/Akt pathway and direct the cytoplasmic localization of p-Akt, stimulates the phosphorylation and activation of PI3K in the C2C12 cells [1]. SY-LB-35 (0.01-10 μM; 24 h) leads the cell cycle shifting to S and G2/M phases in the C2C12 cells [1]. Cell Viability Assay [1] Cell Line: C2C12 cells Concentration: 0.01, 0.1, 1, 10, 100 and 1000 μM Incubation Time: 24 h Result: Stimulated significant increases in cell number and cell viability. Western Blot Analysis [1] Cell Line: C2C12 cells Concentration: 0.01, 0.1, 1 and 10 μM Incubation Time: 30 or 15 min Result: Stimulated Smad phosphorylation and nuclear translocation, activated the PI3K/Akt pathway and direct the cytoplasmic localization of p-Akt, stimulated the phosphorylation and activation of PI3K in the C2C12 cells. Cell Cycle Analysis [1] Cell Line: C2C12 cells Concentration: 0.01, 0.1, 1 and 10 μM Incubation Time: 24 h Result: Caused the cell cycle shifting to S and G2/M phases. |
| molecular weight | 249.27 |
| Molecular formula | C15H11N3O |
| CAS | 2603461-70-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |